Cambrex, a company that supports other pharmaceutical companies in drug development and manufacturing, has expanded its Snapdragon Chemistry facility in WALTHAM, Mass. The expansion, which represents a 20% increase in size, includes new space and updated equipment designed to make the development of peptide-based medicines more efficient and cost-effective.

The expanded facility will allow Snapdragon to manage projects from early-stage experiments through to full-scale drug manufacturing, a streamlined approach intended to accelerate the introduction of new treatments to the market. Cambrex’s primary manufacturing site in Charles city is also critical for scaling up peptide production and has undergone several upgrades.

Past Expansions in Charles City

the Charles City facility has seen significant investment and expansion in recent years to enhance its capabilities. These include:

• In April 2022, the facility completed a $50 million expansion, which boosted its large-scale API manufacturing capacity to approximately 25,000 gallons of reactor capacity, positioning it as one of the most advanced API plants in the U.S.
• This expansion also enhanced the facility’s ability to handle large-scale production of peptides using standard batch reactors.

“This method is designed to bring new treatments to market more quickly.”

Future Impact

The expansion of the Snapdragon Chemistry facility and the ongoing upgrades to the Charles City site highlight Cambrex’s commitment to improving the efficiency and scalability of pharmaceutical manufacturing, particularly in the area of peptide-based medicines.